Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Australian Clinical Labs Ltd ( (AU:ACL) ) has provided an announcement.
Australian Clinical Labs Ltd announced the results of its 2025 Annual General Meeting, where several key resolutions were passed, including the re-election of directors Sarah Butler, Grant Jeffery, Stephen Roche, and Mark Haberlin, as well as the adoption of the 2025 Remuneration Report. The spill resolution was not carried. These outcomes reflect the company’s stable governance structure and commitment to maintaining its leadership team, which may reassure stakeholders about the company’s strategic direction and operational continuity.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.50 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd (ACL) is a leading private provider of pathology services in Australia. The company operates NATA accredited laboratories that conduct a wide range of pathology tests for clients including doctors, specialists, patients, hospitals, and corporate clients. ACL is one of the largest private hospital pathology businesses in the country, focusing on combining talented personnel with medical and scientific leadership to enhance decision-making that improves patient outcomes.
Average Trading Volume: 1,020,011
Technical Sentiment Signal: Sell
Current Market Cap: A$495.4M
For a thorough assessment of ACL stock, go to TipRanks’ Stock Analysis page.